Melanoma cells carrying the mutated BRAF oncogene become addicted to its constitutive activity, which can be therapeutically targeted by kinase inhibitors, such as vemurafenib or its analog PLX-4720, achieving cytostatic and cytotoxic effects [1,2]. The gene discussed is BRAF; the disease is melanoma.